1. Clinical & Scientific Overview
Furosemide (Frusemide) (TIP-MED-000013, Reference Code [3.13]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a High-Ceiling Loop Diuretic (Na+-K+-2Cl- Cotransporter Inhibitor).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.13], p. 27): Lasix (Sanofi), Frusenex (Geno), Combined with Spironolactone: Lasilactone (Sanofi), Fruselac (Lupin) — Strengths & Forms: Oral Tablets: 40 mg (also 20 mg in Lasilactone FDC); Oral Pediatric Solution; Parenteral Injection: 10 mg/mL (2 mL = 20 mg ampoule)
Oral Tablets: 40 mg (also 20 mg in Lasilactone FDC); Oral Pediatric Solution; Parenteral Injection: 10 mg/mL (2 mL = 20 mg ampoule)
3. Mechanism of Action & Pharmacodynamics
Actively secreted into the proximal tubular lumen via Organic Anion Transporters (OAT1/OAT3) and inhibits the luminal Na+-K+-2Cl- (NKCC2 / SLC12A1) cotransporter in the Thick Ascending Limb (TAL) of the Loop of Henle (which reabsorbs 25% of filtered Na+). Abolishes the lumen-positive transepithelial potential, increasing urinary excretion of Na+, Cl-, K+, H+, Mg2+, and Ca2+. IV administration also induces rapid venodilation (within 5–15 min via PGE2 synthesis) before diuresis begins, reducing left ventricular preload in acute pulmonary oedema.
4. Therapeutic Indications & Evidence-Supported Uses
- Acute cardiogenic pulmonary oedema and congestive heart failure volume overload
- Oedema and ascites associated with hepatic cirrhosis or nephrotic syndrome / chronic kidney disease
- Acute severe hypercalcaemia (after adequate normal saline volume resuscitation)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Oral: 20–80 mg once or twice daily (morning and early afternoon). Acute Pulmonary Oedema IV: 40–80 mg slow IV over 2–5 minutes.
Administration & Meal Timing: Oral or slow Intravenous injection (infuse high doses at <=4 mg/min to prevent ototoxicity).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
In hepatic cirrhosis with ascites, hypokalaemia and metabolic alkalosis increase NH3 conversion and can precipitate hepatic encephalopathy — always combine with Spironolactone (ratio 40 mg Furosemide : 100 mg Spironolactone).
Remains effective even in severe CKD (eGFR < 30 mL/min, where thiazides fail), though higher ceiling doses (80–160 mg) are required to reach luminal NKCC2 sites.
In hepatic cirrhosis with ascites, hypokalaemia and metabolic alkalosis increase NH3 conversion and can precipitate hepatic encephalopathy — always combine with Spironolactone (ratio 40 mg Furosemide : 100 mg Spironolactone).
7. Contraindications, Precautions & High-Risk Warnings
- Anuria unresponsive to a trial dose
- Severe hypokalaemia, hyponatraemia, or hypovolaemia/dehydration
- Hepatic coma / severe electrolyte depletion
Key Clinical Precautions: In hepatic cirrhosis with ascites, hypokalaemia and metabolic alkalosis increase NH3 conversion and can precipitate hepatic encephalopathy — always combine with Spironolactone (ratio 40 mg Furosemide : 100 mg Spironolactone).
8. Adverse Effects Profile
- Hypokalaemia, hypomagnesaemia, hyponatraemia, hypocalcaemia, and hypochloraemic metabolic alkalosis
- Hyperuricaemia (competes with uric acid for OAT secretion, precipitating gout) and hyperglycaemia
- Dose-rate-dependent reversible or permanent sensorineural ototoxicity (blocks inner ear stria vascularis NKCC1 when IV rate > 4 mg/min)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Aminoglycosides (Gentamicin, Amikacin) or Cisplatin: synergistic cochlear hair-cell ototoxicity (sensorineural deafness) and nephrotoxicity
- Digoxin: Furosemide-induced hypokalaemia and hypomagnesaemia markedly increase Digoxin binding to Na+/K+-ATPase and trigger fatal arrhythmias
- NSAIDs (Diclofenac, Indomethacin): block renal prostaglandin synthesis and blunt Furosemide natriuresis
- Lithium: volume depletion increases proximal Na+/Li+ reabsorption and precipitates Lithium toxicity
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Take oral doses in the morning (and if twice daily, take the second dose before 2:00–4:00 PM) to avoid nocturnal urination (nocturia).
- Eat potassium-rich foods (coconut water, bananas, citrus fruits, spinach) unless also taking Spironolactone or an ACEi/ARB, as directed by your physician.
- Rise slowly from sitting or lying down to prevent dizziness.
Storage, Stability & Dispensing Safeguards: Store below 30°C protected from light (do not use injection if yellow discolouration is present).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.15] Spironolactone — Potassium-Sparing Diuretic; Mineralocorticoid (Aldosterone) Recep
- [3.16] Atorvastatin Calcium — HMG-CoA Reductase Inhibitor (Lipophilic Statin); Lipid-Lowering &
- [3.17] Rosuvastatin Calcium — HMG-CoA Reductase Inhibitor (Hydrophilic, High-Potency Statin)
- [3.18] Aspirin (Acetylsalicylic Acid — Low-Dose Antiplatelet) — Irreversible Cyclooxygenase-1 (COX-1) Inhibitor; Thromboxane A2 S
